Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis

被引：27

作者：

Yin, Chu-Yang ^{[1
]}

Lin, Xiao-Lin ^{[2
]}

Tian, Lei ^{[2
]}

Ye, Ming ^{[2
]}

Yang, Xin-Ying ^{[3
]}

Xiao, Xiu-Ying ^{[2
]}

机构：

[1] Fudan Univ, Obstet & Gynecol Hosp, Dept Breast Surg, Shanghai 200011, Peoples R China

[2] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Oncol, Shanghai 200127, Peoples R China

[3] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 46期

基金：

中国国家自然科学基金;

关键词：

Gastric cancer; Lobaplatin; Apoptosis; ANTICANCER DRUG DEVELOPMENT; PLATINUM; CYCLE; CHEMOTHERAPY;

D O I：

10.3748/wjg.v20.i46.17426

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To assess the anti-cancer effect of lobaplatin on human gastric cancer cells, and to explore the underlying molecular mechanisms. METHODS: The human gastric cancer cell lines MKN-28, AGS and MKN-45 were used. The cytotoxicity of lobaplatin was detected using an MTS cell proliferation assay. Flow cytometry was used to detect cell apoptosis using Annexin V-FITC Apoptosis Detection Kit. The expression of apoptosis-regulated genes was examined at the protein level using Western blot. RESULTS: Lobaplatin inhibited the proliferation of human gastric cancer cells and induced apoptosis, which may be associated with the up-regulation of Bax expression, poly(ADP-ribose) polymerase (PARP) cleavage, p53 expression and the reduction of Bcl-2 expression. CONCLUSION: The cytotoxicity of lobaplatin may be due to its ability of inducing apoptosis of gastric cancer cells, which would support the potential use of lobaplatin for the therapy of gastric cancer. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

引用

页码：17426 / 17433

页数：8

共 19 条

[1] [Anonymous], 2003, DRUGS R D, V4, P369
[2] P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation
Avery-Kiejda, Kelly A.
Bowden, Nikola A.
Croft, Amanda J.
Scurr, Lyndee L.
Kairupan, Carla F.
Ashton, Katie A.
Talseth-Palmer, Bente A.
Rizos, Helen
Zhang, Xu D.
Scott, Rodney J.
Hersey, Peter
[J]. BMC CANCER, 2011, 11
[3] Fourier Transform Infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives
Berger, Gilles
Gasper, Regis
Lamoral-Theys, Delphine
Wellner, Anja
Gelbcke, Michel
Gust, Ronald
Neve, Jean
Kiss, Robert
Goormaghtigh, Erik
Dufrasne, Francois
[J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 37 (03) : 679 - 686
[4] Del Poeta G, 2008, CURR CANCER DRUG TAR, V8, P207
[5] Farhat FS, 2010, EXPERT REV ANTICANC, V10, P541, DOI [10.1586/era.09.179, 10.1586/ERA.09.179]
[6] Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches
Galanski, M
Jakupec, MA
Keppler, BK
[J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (18) : 2075 - 2094
[7] PRECLINICAL ACTIVITY OF A NEW PLATINUM ANALOG, LOBAPLATIN, IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN TESTICULAR, OVARIAN, AND GASTRIC-CARCINOMA CELL-LINES
HARSTRICK, A
BOKEMEYER, C
SCHARNOFKSE, M
HAPKE, G
REILE, D
SCHMOLL, HJ
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (01) : 43 - 47
[8] Kirpensteijn J, 2002, ANTICANCER RES, V22, P2765
[9] Lobaplatin: a new antitumour platinum drug
McKeage, MJ
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (01) : 119 - 128
[10] Advanced gastric cancer with brain metastasis effectively treated by arterial infusion chemotherapy: A case report
Peng, Zhaohong
Xu, Shengde
Li, Hua
Sun, Chaobin
Fu, Minyan
Gao, Mingzhu
[J]. ONCOLOGY LETTERS, 2014, 7 (02) : 449 - 451

← 1 2 →